As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Inovio Pharmaceuticals Inc. The largest reported stake is Fmr LLC's, at 14.5%. 17 filings are on record since July 17, 2025 (Schedule 13G/A, November 5, 2026).
Who owns Inovio Pharmaceuticals, Inc.?
Sell to companies like Inovio Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 15,364,097 · Shared voting: 0 · Sole dispositive: 15,364,105 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Reporting person: Adage Capital Management, L.P. · Sole voting: 0 · Shared voting: 3,428,571 · Sole dispositive: 0 · Shared dispositive: 3,428,571 · SCHEDULE 13G/A, 2026-08-12
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 10,666,523 · Sole dispositive: 0 · Shared dispositive: 10,666,523 · SCHEDULE 13G, 2026-08-07
- · Holder: Fmr LLC · Percent: 10.3% · SCHEDULE 13G/A
- · Reporting person: Vanguard Capital Management · Sole voting: 511,004 · Shared voting: 0 · Sole dispositive: 4,161,566 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-31
Inovio Pharmaceuticals Inc has 17 Schedule 13D or 13G filings on record since 2025-07-17. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 14.5% | 15,364,105 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
| Janus Henderson Group Plc | 9.99% | 6,666,295 | SCHEDULE 13G/A, 2025-12-08 | 2025-11-28 |
| RA Capital Management, L.P. | 9.9% | 10,666,523 | SCHEDULE 13G, 2026-08-07 | 2026-07-31 |
| Highbridge Capital Management LLC | 8.2% | 6,190,475 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Alyeska Investment Group, L.P. | 5.99% | 4,000,000 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Vanguard Capital Management | 5.05% | 4,161,566 | SCHEDULE 13G, 2026-07-31 | 2026-06-30 |
| The Vanguard Group | 4.96% | 3,315,579 | SCHEDULE 13G/A, 2026-01-30 | 2025-12-31 |
| Adage Capital Management, L.P. | 4% | 3,428,571 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| Deep Track Capital, LP | 2.41% | 1,314,796 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| BlackRock, Inc. | 1.5% | 537,627 | SCHEDULE 13G/A, 2025-07-17 | 2025-06-30 |
Holding shares or following this stake? See who's behind Inovio Pharmaceuticals Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Inovio Pharmaceuticals Inc and the records around it.
Inovio Pharmaceuticals Inc elsewhere on the record
Companies that share a holder
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- Alyeska Investment Group, L.P. also filed stake reports on 81 other companies: ABUNDIA GLOBAL IMPACT GROUP, INC. (Aug 2026), Bakkt, Inc. (Aug 2026), BATTALION OIL CORP (Aug 2026)
- HIGHBRIDGE CAPITAL MANAGEMENT LLC also filed stake reports on 83 other companies: Aeon Acquisition I Corp. (Aug 2026), Alpex Acquisition Corp (Aug 2026), Aperture AC (Aug 2026)
Watch Inovio Pharmaceuticals Inc
Get an email when Inovio Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Inovio Pharmaceuticals Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Inovio Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Inovio Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 15,364,097 | 0 | 15,364,105 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 15,364,105 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| RA Capital Management, L.P. | 0 | 10,666,523 | 0 | 10,666,523 | SCHEDULE 13G, 2026-08-07 |
| Peter Kolchinsky | 0 | 10,666,523 | 0 | 10,666,523 | SCHEDULE 13G, 2026-08-07 |
| Rajeev Shah | 0 | 10,666,523 | 0 | 10,666,523 | SCHEDULE 13G, 2026-08-07 |
| RA Capital Healthcare Fund, L.P. | 0 | 10,666,523 | 0 | 10,666,523 | SCHEDULE 13G, 2026-08-07 |
| Vanguard Capital Management | 511,004 | 0 | 4,161,566 | 0 | SCHEDULE 13G, 2026-07-31 |
| Adage Capital Management, L.P. | 0 | 3,428,571 | 0 | 3,428,571 | SCHEDULE 13G/A, 2026-08-12 |
| Robert Atchinson | 0 | 3,428,571 | 0 | 3,428,571 | SCHEDULE 13G/A, 2026-08-12 |
| Phillip Gross | 0 | 3,428,571 | 0 | 3,428,571 | SCHEDULE 13G/A, 2026-08-12 |
The latest filing identifies Inovio Pharmaceuticals Inc by CUSIP 45773H409 and gives its principal executive office as 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING, PA 19462 (SCHEDULE 13G/A, 2026-11-05).
What the percentages are based on
Due to the Beneficial Ownership Blocker listed in the Pre-Funded Warrants, each Reporting Person's beneficial ownership percentage is 9.99%.RA Capital Management, L.P., SCHEDULE 13G, 2026-08-07
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 1.5% | SCHEDULE 13G/A |
| 2025-11-13 | Adage Capital Management, L.P. | 9.99% | SCHEDULE 13G |
| 2025-11-14 | Deep Track Capital, LP | 2.41% | SCHEDULE 13G/A |
| 2025-11-14 | Alyeska Investment Group, L.P. | 7.53% | SCHEDULE 13G |
| 2025-11-14 | Janus Henderson Group Plc | 6.2% | SCHEDULE 13G |
| 2025-12-05 | Fmr LLC | 14.8% | SCHEDULE 13G |
| 2025-12-08 | Janus Henderson Group Plc | 9.99% | SCHEDULE 13G/A |
| 2026-01-30 | The Vanguard Group | 4.96% | SCHEDULE 13G/A |
| 2026-02-17 | Alyeska Investment Group, L.P. | 5.99% | SCHEDULE 13G/A |
| 2026-05-06 | Fmr LLC | 13.5% | SCHEDULE 13G/A |
| 2026-05-13 | Adage Capital Management, L.P. | 5.84% | SCHEDULE 13G/A |
| 2026-05-15 | Highbridge Capital Management LLC | 8.2% | SCHEDULE 13G/A |
| 2026-07-31 | Vanguard Capital Management | 5.05% | SCHEDULE 13G |
| 2026-08-06 | Fmr LLC | 10.3% | SCHEDULE 13G/A |
| 2026-08-07 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G |
| 2026-08-12 | Adage Capital Management, L.P. | 4% | SCHEDULE 13G/A |
| 2026-11-05 | Fmr LLC | 14.5% | SCHEDULE 13G/A |
Questions about who owns Inovio Pharmaceuticals Inc
Who owns Inovio Pharmaceuticals Inc?
On this page, 6 holders' latest ownership filings report 5% or more of Inovio Pharmaceuticals Inc: Fmr LLC (14.5%, Schedule 13G/A, filed 2026-11-05), Janus Henderson Group Plc (9.99%, Schedule 13G/A, filed 2025-12-08), RA Capital Management, L.P. (9.9%, Schedule 13G, filed 2026-08-07), Highbridge Capital Management LLC (8.2%, Schedule 13G/A, filed 2026-05-15) and Alyeska Investment Group, L.P. (5.99%, Schedule 13G/A, filed 2026-02-17); 1 more is listed above.
Who are the largest shareholders of Inovio Pharmaceuticals Inc?
By the share each holder's latest filing reports, the largest holders of Inovio Pharmaceuticals Inc on this page are Fmr LLC (14.5%), Janus Henderson Group Plc (9.99%) and RA Capital Management, L.P. (9.9%).
When did Fmr LLC buy into Inovio Pharmaceuticals Inc?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2025-12-05, reporting 14.8%; its latest, Schedule 13G/A filed 2026-11-05, reports 14.5%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Inovio Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.